Eiger BioPharmaceuticals ( NASDAQ: EIGR ) added ~6% pre-market Thursday after announcing that The New England Journal of Medicine published data from the investigator-sponsored Phase 3 TOGETHER Study for its experimental COVID therapy peginterferon lambda.
In September, Eiger ( EIGR ) said that the FDA was not certain if the company could meet the requirements for a EUA submission for peginterferon lambda in the U.S.
TOGETHER Study involved a predominantly vaccinated population, with 84% of the subjects having received COVID vaccination before enrollment.
The results, as published, indicate a 51% reduction in the risk of hospitalizations and emergency room visits longer than six hours in those who received a single subcutaneous injection of peginterferon lambda.
The peer-reviewed publication comes at a time when the newly emerging COVID variants render vaccines and antibody therapies ineffective.
“…but this may not be a concern with peginterferon lambda due to its mechanism of action that involves activation of multiple virus-killing pathways,” said Jordan Feld, an Associate Professor of Medicine at the University of Toronto and co-Lead Investigator for TOGETHER.
Amid an ongoing evaluation of its portfolio, the company intends to seek ex-US emergency use of peginterferon lambda for COVID-19.
Read: Seeking Alpha contributor Bret Jensen issued a Buy rating on Eiger ( EIGR ) in November alongside a complete investment analysis.
For further details see:
Eiger gains as journal publishes late-stage data on COVID therapy